364 related articles for article (PubMed ID: 31838548)
1. Use of proton pump inhibitors in adults in France: a nationwide drug utilization study.
Lassalle M; Le Tri T; Bardou M; Biour M; Kirchgesner J; Rouby F; Dumarcet N; Zureik M; Dray-Spira R
Eur J Clin Pharmacol; 2020 Mar; 76(3):449-457. PubMed ID: 31838548
[TBL] [Abstract][Full Text] [Related]
2. Proton pump inhibitor utilisation and potentially inappropriate prescribing analysis: insights from a single-centred retrospective study.
Liu Y; Zhu X; Li R; Zhang J; Zhang F
BMJ Open; 2020 Nov; 10(11):e040473. PubMed ID: 33243802
[TBL] [Abstract][Full Text] [Related]
3. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
[TBL] [Abstract][Full Text] [Related]
4. Is there overuse of proton pump inhibitors in B-cell non-Hodgkin lymphomas? A cohort study based on the French health insurance database in the Midi-Pyrénées region.
Conte C; Bourrel R; Despas F; Lapeyre-Mestre M
Fundam Clin Pharmacol; 2019 Jun; 33(3):327-338. PubMed ID: 30625254
[TBL] [Abstract][Full Text] [Related]
5. Use of proton pump inhibitors with lack of diagnostic indications in 22 Midwestern US skilled nursing facilities.
Patterson Burdsall D; Flores HC; Krueger J; Garretson S; Gorbien MJ; Iacch A; Dobbs V; Homa T
J Am Med Dir Assoc; 2013 Jun; 14(6):429-32. PubMed ID: 23583000
[TBL] [Abstract][Full Text] [Related]
6. Proton-pump inhibitor utilization associated with the change to nonpreferred formulary status for esomeprazole in the TRICARE formulary.
Linton A; Bacon T; Peterson M
J Manag Care Pharm; 2009; 15(1):42-54. PubMed ID: 19125549
[TBL] [Abstract][Full Text] [Related]
7. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression.
Scarpignato C; Gatta L; Zullo A; Blandizzi C; ;
BMC Med; 2016 Nov; 14(1):179. PubMed ID: 27825371
[TBL] [Abstract][Full Text] [Related]
8. Results of an intervention in an academic Internal Medicine Clinic to continue, step-down, or discontinue proton pump inhibitor therapy related to a tennessee medicaid formulary change.
Ramser KL; Sprabery LR; Hamann GL; George CM; Will A
J Manag Care Pharm; 2009 May; 15(4):344-50. PubMed ID: 19422274
[TBL] [Abstract][Full Text] [Related]
9. The use of proton pump inhibitors in an Italian hospital: focus on oncologic and critical non-ICU patients.
Meli M; Raffa MP; Malta R; Morreale I; Aprea L; D'Alessandro N
Int J Clin Pharm; 2015 Dec; 37(6):1152-61. PubMed ID: 26319396
[TBL] [Abstract][Full Text] [Related]
10. Appropriate proton pump inhibitors use in elderly outpatients according to recommendations.
Schonheit C; Le Petitcorps H; Pautas É
Geriatr Psychol Neuropsychiatr Vieil; 2016 Dec; 14(4):383-388. PubMed ID: 27694063
[TBL] [Abstract][Full Text] [Related]
11. Long-term use of proton pump inhibitors and prevalence of disease- and drug-related reasons for gastroprotection-a cross-sectional population-based study.
Wallerstedt SM; Fastbom J; Linke J; Vitols S
Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):9-16. PubMed ID: 27859947
[TBL] [Abstract][Full Text] [Related]
12. Proton pump inhibitors prescriptions in France: Main trends from 2006 to 2016 on French health insurance database.
Boucherie Q; Rouby F; Frankel D; Roll P; Micallef J
Therapie; 2018 Oct; 73(5):385-388. PubMed ID: 29778306
[TBL] [Abstract][Full Text] [Related]
13. Co-prescribing of proton pump inhibitors among chronic users of NSAIDs in the UK.
Suh DC; Hunsche E; Shin HC; Mavros P
Rheumatology (Oxford); 2008 Apr; 47(4):458-63. PubMed ID: 18263598
[TBL] [Abstract][Full Text] [Related]
14. Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period.
Haastrup PF; Paulsen MS; Christensen RD; Søndergaard J; Hansen JM; Jarbøl DE
Aliment Pharmacol Ther; 2016 Jul; 44(1):78-87. PubMed ID: 27137875
[TBL] [Abstract][Full Text] [Related]
15. National Study of Off-label Proton Pump Inhibitor Use Among New Zealand Infants in the First Year of Life (2005-2012).
Blank ML; Parkin L
J Pediatr Gastroenterol Nutr; 2017 Aug; 65(2):179-184. PubMed ID: 28403034
[TBL] [Abstract][Full Text] [Related]
16. [Impact of an evaluation of the professional practices on the relevance of proton pump inhibitors prescriptions pertinence at the hospital].
Daumas A; Garros E; Mendizabal H; Gayet S; Bernard F; Bagnères D; Demoux AL; Rossi P; Villani P; Granel B
Rev Med Interne; 2018 Aug; 39(8):618-626. PubMed ID: 29628172
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic intent of proton pump inhibitor prescription among elderly nonsteroidal anti-inflammatory drug users.
Dries AM; Richardson P; Cavazos J; Abraham NS
Aliment Pharmacol Ther; 2009 Sep; 30(6):652-61. PubMed ID: 19573167
[TBL] [Abstract][Full Text] [Related]
18. Who gets prescriptions for proton pump inhibitors and why? A drug-utilization study with claims data in Bavaria, Germany, 2010-2018.
Rückert-Eheberg IM; Nolde M; Ahn N; Tauscher M; Gerlach R; Güntner F; Günter A; Meisinger C; Linseisen J; Amann U; Baumeister SE
Eur J Clin Pharmacol; 2022 Apr; 78(4):657-667. PubMed ID: 34877614
[TBL] [Abstract][Full Text] [Related]
19. Passing the acid test? Evaluating the impact of national education initiatives to reduce proton pump inhibitor use in Australia.
Bruno C; Pearson SA; Daniels B; Buckley NA; Schaffer A; Zoega H
BMJ Qual Saf; 2020 May; 29(5):365-373. PubMed ID: 31641029
[TBL] [Abstract][Full Text] [Related]
20. Socio-demographic factors influence chronic proton pump inhibitor use by a large population in the Netherlands.
van Boxel OS; Hagenaars MP; Smout AJ; Siersema PD
Aliment Pharmacol Ther; 2009 Mar; 29(5):571-9. PubMed ID: 19035978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
